Detail
Článek
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Efficacy and safety of weekly carfilzomib (70 mg/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies

X. Leleu, M. Beksac, T. Chou, M. Dimopoulos, SS. Yoon, HM. Prince, L. Pour, T. Shelekhova, A. Chari, M. Khurana, J. Zhang, M. Obreja, M. Qi, A. Oriol, D. Siegel

. 2021 ; 62 (2) : 358-367. [pub] 20201028

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21019353

The regimen of carfilzomib, daratumumab, and dexamethasone (KdD) shows activity in patients with relapsed/refractory multiple myeloma. KdD at the twice-weekly 56 mg/m2 carfilzomib dose (KdD56) was used in the randomized phase 3 CANDOR study (NCT03158688), whereas KdD at the once-weekly 70 mg/m2 carfilzomib dose (KdD70) was used in the phase 1 b EQUULEUS study (NCT01998971). We analyzed efficacy data from comparable CANDOR and EQUULEUS patients using inverse probability of treatment weighting (IPTW)-adjusted models. These weights were calculated from propensity scores derived to balance prespecified baseline covariates. The side-by-side and adjusted comparisons showed similar efficacy for overall response rates and progression-free survival in the two groups, with a series of sensitivity analyses showing consistent findings. Safety data were generally consistent with the known safety profiles of each individual drug. Once-weekly KdD70 is comparable to twice-weekly KdD56 in terms of efficacy and safety while being a more convenient dosing option.

000      
00000naa a2200000 a 4500
001      
bmc21019353
003      
CZ-PrNML
005      
20210830100926.0
007      
ta
008      
210728s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1080/10428194.2020.1832672 $2 doi
035    __
$a (PubMed)33112184
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Leleu, Xavier $u Service d'Hématologie et Thérapie cellulaire, CHU and Inserm, Poitiers, France
245    10
$a Efficacy and safety of weekly carfilzomib (70 mg/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies / $c X. Leleu, M. Beksac, T. Chou, M. Dimopoulos, SS. Yoon, HM. Prince, L. Pour, T. Shelekhova, A. Chari, M. Khurana, J. Zhang, M. Obreja, M. Qi, A. Oriol, D. Siegel
520    9_
$a The regimen of carfilzomib, daratumumab, and dexamethasone (KdD) shows activity in patients with relapsed/refractory multiple myeloma. KdD at the twice-weekly 56 mg/m2 carfilzomib dose (KdD56) was used in the randomized phase 3 CANDOR study (NCT03158688), whereas KdD at the once-weekly 70 mg/m2 carfilzomib dose (KdD70) was used in the phase 1 b EQUULEUS study (NCT01998971). We analyzed efficacy data from comparable CANDOR and EQUULEUS patients using inverse probability of treatment weighting (IPTW)-adjusted models. These weights were calculated from propensity scores derived to balance prespecified baseline covariates. The side-by-side and adjusted comparisons showed similar efficacy for overall response rates and progression-free survival in the two groups, with a series of sensitivity analyses showing consistent findings. Safety data were generally consistent with the known safety profiles of each individual drug. Once-weekly KdD70 is comparable to twice-weekly KdD56 in terms of efficacy and safety while being a more convenient dosing option.
650    _2
$a monoklonální protilátky $7 D000911
650    12
$a protokoly antitumorózní kombinované chemoterapie $x škodlivé účinky $7 D000971
650    _2
$a dexamethason $x terapeutické užití $7 D003907
650    _2
$a lidé $7 D006801
650    12
$a mnohočetný myelom $x farmakoterapie $7 D009101
650    _2
$a oligopeptidy $x škodlivé účinky $7 D009842
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Beksac, Meral $u Department of Hematology, Ankara University, Ankara, Turkey
700    1_
$a Chou, Takaaki $u Department of Internal Medicine, Niigata Cancer Center Hospital, Niigata, Japan
700    1_
$a Dimopoulos, Meletios $u Hematology and Medical Oncology, Department of Clinical Therapeutics, National and Kapodistrian University of Athens School of Medicine, Athens, Greece
700    1_
$a Yoon, Sung-Soo $u Department of Internal Medicine, Seoul National University, Seoul, South Korea
700    1_
$a Prince, H Miles $u Epworth Healthcare and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia
700    1_
$a Pour, Ludek $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic
700    1_
$a Shelekhova, Tatiana $u Clinic of Professional Pathology, Saratov, Russian Federation
700    1_
$a Chari, Ajai $u Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
700    1_
$a Khurana, Monica $u Clinical Development, Oncology, Amgen Inc., Thousand Oaks, CA, USA
700    1_
$a Zhang, Jianqi $u Global Biostatistical Science, Amgen Inc., Thousand Oaks, CA, USA
700    1_
$a Obreja, Mihaela $u Global Biostatistical Science, Amgen Inc., Thousand Oaks, CA, USA
700    1_
$a Qi, Ming $u Hematology and Oncology, Janssen Research and Development, LLC, Spring House, PA, USA
700    1_
$a Oriol, Albert $u Institut Català d'Oncologia and Josep Carreras Research Leukaemia Institute, Hospital Germans Trias i Pujol, Barcelona, Spain
700    1_
$a Siegel, David $u John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA
773    0_
$w MED00003140 $t Leukemia & lymphoma $x 1029-2403 $g Roč. 62, č. 2 (2021), s. 358-367
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33112184 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830100926 $b ABA008
999    __
$a ok $b bmc $g 1690228 $s 1139799
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 62 $c 2 $d 358-367 $e 20201028 $i 1029-2403 $m Leukemia & lymphoma $n Leuk Lymphoma $x MED00003140
LZP    __
$a Pubmed-20210728

Najít záznam

Citační ukazatele

Možnosti archivace